FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281710573> ?p ?o ?g. }

• W4281710573 endingPage "3107" @default.
• W4281710573 startingPage "3107" @default.
• W4281710573 abstract "3107 Background: T regulatory (Tregs) cells contribute to immune suppression in cancer. The highly selective inhibitor of PI3Kδ, IOA-244, blocks the activity of Tregs among other things, thus reprograms the anti-tumor immune response. Methods: IOA-244 was investigated in a two-part FIH study. Part A explored the continuous daily dosing of IOA-244 at 10, 20, 40 and 80 mg. Part B consists of expansion cohorts of specific tumor indications, including pre-treated uveal melanoma patients (pts). Primary objective: safety of the anticipated biologically effective dose (BED), or the recommended phase 2 dose (RP2D). Secondary objectives: PK; PD (e.g., inhibition of CD63 expression on basophils, changes in immune cell subsets in peripheral blood); RECIST 1.1.-based responses; PFS and OS. Exploratory studies: changes in circulating immune cells by Cytometry by Time of Flight (CyTOF); response assessments by radiomics Results: Part A Solid Tumor (completed): Sixteen pts were treated in 4 cohorts each with 4 pts. Pts characteristics: uveal melanoma (9/16; 56%), cutaneous melanoma (5/16; 31%) and pleural mesothelioma (2/16; 13%). Four pts had at least one serious TEAE, none considered related to IOA-244. There was no treatment-emergent adverse events (TEAE) leading to study drug discontinuation, immune related toxicity or Dose Limiting Toxicity. CTCAE v5 Grade 1 and 2 were observed, including 2 cases of transient diarrhoea and 2 of AST/ALT elevation. Part A (Completed) – Subgroup Uveal Melanoma Pts (progressed ≥1 line prior therapy): 9 pts treated (3/9 pts ongoing). Mean time on treatment: 7.7 mo (range: 1.8-16.0 mo with 3 pts ongoing). ORR (RECIST 1.1): CR+PR: 0/9 (0%); SD: 6/9 (67%). Median OS: 5.4 mo - not determined (% alive at 1 year: 44% with 3 pts ongoing). CT images from 7/9 patients were assessed for changes in their metastatic lesions by radiomics (baseline and Week 8). Based on 147 matched lesions, 19% had complete responses and 16% had new lesions. In the liver, non-progressive disease was observed in 61% of all lesions, including 42% with either complete response or volume reduction of more than 30%. Using CyTOF, circulating Tregs were reduced while CD8 and NK cells were increased. Part B Uveal Melanoma Expansion Cohort (ongoing): 7 patients (7/7 pts ongoing); mean time on treatment 3.7 mo. ORR (RECIST 1.1): SD in 4/7 pts (57%). Part A Follicular Lymphoma Cohort (ongoing): At 20 mg: 4/4 pts. No DLT. At 80 mg: recruiting. Conclusions: In addition to being well tolerated, IOA-244 at the 80 mg dose shows reduction in peripheral blood Tregs and anti-tumor responses based on radiomics. Therefore, RECIST 1.1.-derived SD may underestimate anti-tumor activity of IOA-244 in treatment-resistant uveal melanoma. Additional patients will be treated to further refine this radiomics-based observation. Clinical trial information: NCT04328844." @default.
• W4281710573 created "2022-06-13" @default.
• W4281710573 creator A5002085922 @default.
• W4281710573 creator A5004497401 @default.
• W4281710573 creator A5021465650 @default.
• W4281710573 creator A5029312514 @default.
• W4281710573 creator A5033549340 @default.
• W4281710573 creator A5033684622 @default.
• W4281710573 creator A5037568604 @default.
• W4281710573 creator A5038656790 @default.
• W4281710573 creator A5042459008 @default.
• W4281710573 creator A5046509076 @default.
• W4281710573 creator A5049799323 @default.
• W4281710573 creator A5052152939 @default.
• W4281710573 creator A5054773035 @default.
• W4281710573 creator A5067252638 @default.
• W4281710573 creator A5068455130 @default.
• W4281710573 creator A5070504013 @default.
• W4281710573 creator A5074970142 @default.
• W4281710573 creator A5076200740 @default.
• W4281710573 creator A5076391983 @default.
• W4281710573 creator A5082045927 @default.
• W4281710573 date "2022-06-01" @default.
• W4281710573 modified "2023-10-01" @default.
• W4281710573 title "First-in-human (FIH) phase I study of the highly selective phosphoinositide 3-kinase inhibitor delta (PI3Kδ) inhibitor IOA-244 in patients with advanced cancer: Safety, activity, pharmacokinetic (PK), and pharmacodynamic (PD) results." @default.
• W4281710573 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.3107" @default.
• W4281710573 hasPublicationYear "2022" @default.
• W4281710573 type Work @default.
• W4281710573 citedByCount "1" @default.
• W4281710573 countsByYear W42817105732023 @default.
• W4281710573 crossrefType "journal-article" @default.
• W4281710573 hasAuthorship W4281710573A5002085922 @default.
• W4281710573 hasAuthorship W4281710573A5004497401 @default.
• W4281710573 hasAuthorship W4281710573A5021465650 @default.
• W4281710573 hasAuthorship W4281710573A5029312514 @default.
• W4281710573 hasAuthorship W4281710573A5033549340 @default.
• W4281710573 hasAuthorship W4281710573A5033684622 @default.
• W4281710573 hasAuthorship W4281710573A5037568604 @default.
• W4281710573 hasAuthorship W4281710573A5038656790 @default.
• W4281710573 hasAuthorship W4281710573A5042459008 @default.
• W4281710573 hasAuthorship W4281710573A5046509076 @default.
• W4281710573 hasAuthorship W4281710573A5049799323 @default.
• W4281710573 hasAuthorship W4281710573A5052152939 @default.
• W4281710573 hasAuthorship W4281710573A5054773035 @default.
• W4281710573 hasAuthorship W4281710573A5067252638 @default.
• W4281710573 hasAuthorship W4281710573A5068455130 @default.
• W4281710573 hasAuthorship W4281710573A5070504013 @default.
• W4281710573 hasAuthorship W4281710573A5074970142 @default.
• W4281710573 hasAuthorship W4281710573A5076200740 @default.
• W4281710573 hasAuthorship W4281710573A5076391983 @default.
• W4281710573 hasAuthorship W4281710573A5082045927 @default.
• W4281710573 hasConcept C111113717 @default.
• W4281710573 hasConcept C112705442 @default.
• W4281710573 hasConcept C121608353 @default.
• W4281710573 hasConcept C126322002 @default.
• W4281710573 hasConcept C143998085 @default.
• W4281710573 hasConcept C197934379 @default.
• W4281710573 hasConcept C203014093 @default.
• W4281710573 hasConcept C2777658100 @default.
• W4281710573 hasConcept C2778715236 @default.
• W4281710573 hasConcept C29730261 @default.
• W4281710573 hasConcept C502942594 @default.
• W4281710573 hasConcept C71924100 @default.
• W4281710573 hasConcept C8891405 @default.
• W4281710573 hasConcept C98274493 @default.
• W4281710573 hasConceptScore W4281710573C111113717 @default.
• W4281710573 hasConceptScore W4281710573C112705442 @default.
• W4281710573 hasConceptScore W4281710573C121608353 @default.
• W4281710573 hasConceptScore W4281710573C126322002 @default.
• W4281710573 hasConceptScore W4281710573C143998085 @default.
• W4281710573 hasConceptScore W4281710573C197934379 @default.
• W4281710573 hasConceptScore W4281710573C203014093 @default.
• W4281710573 hasConceptScore W4281710573C2777658100 @default.
• W4281710573 hasConceptScore W4281710573C2778715236 @default.
• W4281710573 hasConceptScore W4281710573C29730261 @default.
• W4281710573 hasConceptScore W4281710573C502942594 @default.
• W4281710573 hasConceptScore W4281710573C71924100 @default.
• W4281710573 hasConceptScore W4281710573C8891405 @default.
• W4281710573 hasConceptScore W4281710573C98274493 @default.
• W4281710573 hasIssue "16_suppl" @default.
• W4281710573 hasLocation W42817105731 @default.
• W4281710573 hasOpenAccess W4281710573 @default.
• W4281710573 hasPrimaryLocation W42817105731 @default.
• W4281710573 hasRelatedWork W1758514097 @default.
• W4281710573 hasRelatedWork W1997101420 @default.
• W4281710573 hasRelatedWork W2002058825 @default.
• W4281710573 hasRelatedWork W2010116591 @default.
• W4281710573 hasRelatedWork W2090099591 @default.
• W4281710573 hasRelatedWork W2108417615 @default.
• W4281710573 hasRelatedWork W2227061539 @default.
• W4281710573 hasRelatedWork W2410816841 @default.
• W4281710573 hasRelatedWork W2594910449 @default.
• W4281710573 hasRelatedWork W2992709639 @default.
• W4281710573 hasVolume "40" @default.
• W4281710573 isParatext "false" @default.
• W4281710573 isRetracted "false" @default.
• W4281710573 workType "article" @default.